Igene Biotechnology Return On Asset vs. Book Value Per Share
Based on the key profitability measurements obtained from Igene Biotechnology's financial statements, Igene Biotechnology may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Igene Biotechnology's ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis.
For Igene Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Igene Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Igene Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Igene Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Igene Biotechnology over time as well as its relative position and ranking within its peers.
Igene |
Igene Biotechnology Book Value Per Share vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Igene Biotechnology's current stock value. Our valuation model uses many indicators to compare Igene Biotechnology value to that of its competitors to determine the firm's financial worth. Igene Biotechnology is rated third overall in return on asset category among its peers. It is rated fourth overall in book value per share category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Igene Biotechnology's earnings, one of the primary drivers of an investment's value.Igene Book Value Per Share vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Igene Biotechnology |
| = | -0.0821 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Igene Biotechnology |
| = | (0) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Igene Book Value Per Share Comparison
Igene Biotechnology is currently under evaluation in book value per share category among its peers.
Igene Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Igene Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Igene Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Igene Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Igene Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.
Igene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Igene Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Igene Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Igene Biotechnology's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Igene Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Use Investing Themes to Complement your Igene Biotechnology position
In addition to having Igene Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Igene Pink Sheet
To fully project Igene Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Igene Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Igene Biotechnology's income statement, its balance sheet, and the statement of cash flows.